Clinical Trial Update: Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas [Phase 2]

View source ↗

Summary

Phase 2 trial of sunitinib (Sutent) in neurofibromatosis type 1 with plexiform neurofibromas was terminated; results were posted on 2016-05-04.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Indiana University | Conditions: Neurofibromatosis, NF1 | Phase 2 | Status: TERMINATED | Results posted: 2016-05-04